한글목차

종양 미세환경 동향 및 예측

세계의 종양 미세환경 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 11.2%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 암 이환율의 상승, 면역종양학에서의 종양 미세환경의 중요성이 높아지고, 또한 정부와 제약기업이 종양학 연구에 대한 투자를 강화하고 있다는 것입니다. 세계의 종양 미세환경 시장의 미래는 바이오제약회사, 병원, 진단검사실, 연구기관, CRO의 각 시장에서의 기회에 의해 유망시되고 있습니다.

부문별 종양 미세환경

본 조사에서는 세계의 종양 미세환경에 대해 암 유형별, 제품별, 치료법별, 최종 용도별, 지역별 예측을 제공합니다.

종양 미세환경 시장 인사이트

Lucintel은 예측 기간 동안에도 폐암이 가장 큰 부문으로 유지될 것으로 예측했습니다.

이 시장에서는 바이오 의약품 기업이 계속해서 최대 부문이 됩니다.

북미는 최신 기술의 도입이 진행되고 있는 것, 생명 과학 연구를 위한 정부로부터의 자금 원조, 대기업 제약 기업이나 바이오 테크놀로지 기업이 진출하고 있는 것 등으로부터, 예측 기간 중에도 최대 지역으로 계속됩니다.

FAQ

Q1. 시장의 성장 예측은 :

A1. 세계의 종양 미세환경 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 11.2%로 성장할 것으로 예상됩니다.

Q2. 시장 성장에 영향을 미치는 주요 촉진요인은 :

A2. 이 시장의 주요 촉진요인은 암 유병률 증가, 면역종양학에서 종양 미세환경의 중요성 증가, 정부 및 제약 기업이 종양학 연구에 대한 투자를 강화하고 있다 입니다.

Q3. 시장의 주요 부문은 :

A3. 세계 종양 미세환경 시장의 미래는 바이오의약품 회사, 병원, 진단검사실, 연구기관, CRO의 각 시장에서의 기회에 의해 유망시되고 있습니다.

Q4. 시장의 주요 기업은 :

A4. 주요 종양 미세환경 기업은 다음과 같습니다.

• Thermo Fisher Scientific
• Illumina
• Danaher
• Merck
• BD Biosciences
• Promega
• Bio-Techne
• Bio-Rad Laboratories
• Hoffmann-La Roche
• QIAGEN

Q5. 향후 가장 큰 시장 부문은 :

A5. Lucintel은 예측 기간 동안 폐암이 가장 큰 부문인 것을 계속할 것으로 예측됩니다.

Q6. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은 :

A6. 북미는 최신 기술의 도입이 진행되고 있는 것, 생명 과학 연구에 대한 정부로부터의 자금 원조, 대기업 제약 기업이나 바이오 테크놀로지 기업이 진출하고 있기 때문에 예측 기간 중에도 최대 지역으로 계속될 것으로 보입니다.

Q7. 보고서 사용자 정의는 가능한가?

A7. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 종양 미세환경 시장 : 시장 역학

• 서문, 배경 및 분류
• 공급망
• 업계의 촉진요인 및 과제

제3장 시장 동향 및 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 종양 미세환경 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 종양 미세환경 시장 : 암 유형별
  • 폐암
  • 대장암
  • 유방암
  • 전립선암
  • 방광암
  • 기타
• 세계의 종양 미세환경 시장 : 제품별
  • T세포
  • 종양 관련 대식세포
  • 골수 유래 억제 세포
  • 암 관련 섬유아세포
  • 제어성 T 세포
  • 기타
• 세계의 종양 미세환경 시장 : 치료법별
  • 단클론항체
  • 사이토카인
  • 암 백신
  • 종양 용해성 바이러스
  • 입양세포치료
  • 기타
• 세계의 종양 미세환경 시장 : 최종 용도별
  • 바이오의약품기업
  • 병원
  • 진단 실험실
  • 연구기관
  • CRO(의약품 개발 업무 수탁 기관)
  • 기타

제4장 시장 동향 및 예측 분석(2018-2023년) : 지역별

• 지역별 세계의 종양 미세환경 시장
• 북미의 종양 미세환경 시장
• 유럽의 종양 미세환경 시장
• 아시아태평양 종양 미세환경 시장
• 기타 지역의 종양 미세환경 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회 및 전략 분석

• 성장 기회 분석
  • 암 유형별 세계 종양 미세환경 시장의 성장 기회
  • 제품별 세계 종양 미세환경 시장의 성장 기회
  • 치료법별 세계 종양 미세환경 시장의 성장 기회
  • 최종 용도별 세계 종양 미세환경 시장의 성장 기회
  • 지역별 세계 종양 미세환경 시장의 성장 기회
• 세계의 종양 미세환경 시장에서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계 종양 미세환경 시장의 능력 확대
  • 세계 종양 미세환경 시장의 합병, 인수 및 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• Thermo Fisher Scientific
• Illumina
• Danaher
• Merck
• BD Biosciences
• Promega
• Bio-Techne
• Bio-Rad Laboratories
• Hoffmann-La Roche
• QIAGEN

영문목차

Tumor Microenvironment Trends and Forecast

The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets. The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Tumor Microenvironment by Segment

The study includes a forecast for the global tumor microenvironment by cancer type, product, therapy, end use, and region.

Tumor Microenvironment Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Bladder Cancer
• Others

Tumor Microenvironment Market by Product [Shipment Analysis by Value from 2018 to 2030]:

• T Cells
• Tumor-Associated Macrophages
• Myeloid-Derived Suppressor Cells
• Cancer-Associated Fibroblasts
• Regulatory T Cells
• Others

Tumor Microenvironment Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

• Monoclonal Antibodies
• Cytokines
• Cancer Vaccines
• Oncolytic Viruses
• Adoptive Cell Therapies
• Others

Tumor Microenvironment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Biopharmaceutical Companies
• Hospital
• Diagnostic Laboratories
• Research Institutes
• Contract Research Organizations
• Others

Tumor Microenvironment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Tumor Microenvironment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tumor microenvironment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tumor microenvironment companies profiled in this report include-

• Thermo Fisher Scientific
• Illumina
• Danaher
• Merck
• BD Biosciences
• Promega
• Bio-Techne
• Bio-Rad Laboratories
• Hoffmann-La Roche
• QIAGEN

Tumor Microenvironment Market Insights

Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Within this market, biopharmaceutical company will remain the largest segment.

North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Features of the Global Tumor Microenvironment Market

Market Size Estimates: Tumor microenvironment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Tumor microenvironment market size by cancer type, product, therapy, end use, and region in terms of value ($B).

Regional Analysis: Tumor microenvironment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, product, therapy, end use, and regions for the tumor microenvironment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tumor microenvironment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for tumor microenvironment market?

Answer: The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the tumor microenvironment market?

Answer: The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

Q3. What are the major segments for tumor microenvironment market?

Answer: The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets.

Q4. Who are the key tumor microenvironment market companies?

Answer: Some of the key tumor microenvironment companies are as follows:

• Thermo Fisher Scientific
• Illumina
• Danaher
• Merck
• BD Biosciences
• Promega
• Bio-Techne
• Bio-Rad Laboratories
• Hoffmann-La Roche
• QIAGEN

Q5. Which tumor microenvironment market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Q6. In tumor microenvironment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the tumor microenvironment market by cancer type (lung cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, and others), product (T cells, tumor-associated macrophages, myeloid-derived suppressor cells, cancer-associated fibroblasts, regulatory t cells, and others), therapy (monoclonal antibodies, cytokines, cancer vaccines, oncolytic viruses, adoptive cell therapies, and others), end use (biopharmaceutical companies, hospital, diagnostic laboratories, research institutes, contract research organizations, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Tumor Microenvironment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Tumor Microenvironment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Tumor Microenvironment Market by Cancer Type
  • 3.3.1: Lung Cancer
  • 3.3.2: Colorectal Cancer
  • 3.3.3: Breast Cancer
  • 3.3.4: Prostate Cancer
  • 3.3.5: Bladder Cancer
  • 3.3.6: Others
• 3.4: Global Tumor Microenvironment Market by Product
  • 3.4.1: T Cells
  • 3.4.2: Tumor-Associated Macrophages
  • 3.4.3: Myeloid-Derived Suppressor Cells
  • 3.4.4: Cancer-Associated Fibroblasts
  • 3.4.5: Regulatory T Cells
  • 3.4.6: Others
• 3.5: Global Tumor Microenvironment Market by Therapy
  • 3.5.1: Monoclonal Antibodies
  • 3.5.2: Cytokines
  • 3.5.3: Cancer Vaccines
  • 3.5.4: Oncolytic Viruses
  • 3.5.5: Adoptive Cell Therapies
  • 3.5.6: Others
• 3.6: Global Tumor Microenvironment Market by End Use
  • 3.6.1: Biopharmaceutical Companies
  • 3.6.2: Hospital
  • 3.6.3: Diagnostic Laboratories
  • 3.6.4: Research Institutes
  • 3.6.5: Contract Research Organizations
  • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Tumor Microenvironment Market by Region
• 4.2: North American Tumor Microenvironment Market
  • 4.2.1: North American Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
  • 4.2.2: North American Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
• 4.3: European Tumor Microenvironment Market
  • 4.3.1: European Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
  • 4.3.2: European Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
• 4.4: APAC Tumor Microenvironment Market
  • 4.4.1: APAC Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
  • 4.4.2: APAC Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
• 4.5: ROW Tumor Microenvironment Market
  • 4.5.1: ROW Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
  • 4.5.2: ROW Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Tumor Microenvironment Market by Cancer Type
  • 6.1.2: Growth Opportunities for the Global Tumor Microenvironment Market by Product
  • 6.1.3: Growth Opportunities for the Global Tumor Microenvironment Market by Therapy
  • 6.1.4: Growth Opportunities for the Global Tumor Microenvironment Market by End Use
  • 6.1.5: Growth Opportunities for the Global Tumor Microenvironment Market by Region
• 6.2: Emerging Trends in the Global Tumor Microenvironment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Tumor Microenvironment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tumor Microenvironment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: Illumina
• 7.3: Danaher
• 7.4: Merck
• 7.5: BD Biosciences
• 7.6: Promega
• 7.7: Bio-Techne
• 7.8: Bio-Rad Laboratories
• 7.9: Hoffmann-La Roche
• 7.10: QIAGEN